ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Inflammation"

  • Abstract Number: 1086 • ACR Convergence 2021

    Lack of Effect of SARS-CoV-2 Vaccination on Cell Bound Complement Activation Products (CB-CAPs), Multianalyte Assay Panel (MAP) with Algorithm, and Inflammatory Biomarkers

    Mark Rudolph, Anja Kammensheidt and Roberta Alexander, Exagen Inc., Vista, CA

    Background/Purpose: SARS-CoV-2 infection can lead to severe inflammation including increased complement activation (Ma, Kulkarni 2021) and the production of several proinflammatory cytokines. The rapid deployment…
  • Abstract Number: 1498 • ACR Convergence 2021

    Platelet Secreted LGALS3BP Induces a Pro-inflammatory Phenotype in Systemic Lupus Erythematosus

    Hanane EL Bannoudi1, MacIntosh Cornwell2, Elliot Luttrell-Williams2, Alexis Engel3, Christina Rolling1, Peter Izmirly4, H. Michael Belmont5, Kelly Ruggles2, Robert Clancy6, Jill Buyon5 and Jeffrey Berger2, 1NYU Langone Health, New York, NY, 2New York University, New York, NY, 3NYU Langone Health, New Yok, NY, 4New York University School of Medicine, New York, NY, 5NYU School of Medicine, New York, NY, 6NYU Grossman School of Medicine, New York, NY

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex chronic heterogeneous autoimmune disease, which increases the risk of atherothrombosis. In addition to their well described role…
  • Abstract Number: 0185 • ACR Convergence 2021

    Phase 1 Study Results of GS-5718, an Oral IRAK4-Inhibitor: Pharmacodynamics of Single and Multiple Doses of GS-5718 in Healthy Subjects

    Silke Roedder1, Emily Wendt2, Chad Burris2, Jonathan Nazareon2, Grace Park3, Phil Pangilinan2, Gianna Huang2, Anubhav Mathur2, James Taylor2, Andrew Billin2 and Franziska Matzkies4, 1Gilead Sciences, Menlo Park, CA, 2Gilead Sciences, Foster City, CA, 3Gilead Sciences, Seattle, WA, 4Gilead Sciences, Inc., Foster City, CA

    Background/Purpose: Adaptive and innate immune pathways are involved in inflammation and pathogenesis of autoimmune diseases including Rheumatoid Arthritis (RA) and Lupus Erythematosus (LE). Immune complexes…
  • Abstract Number: 0694 • ACR Convergence 2021

    Glucagon-like Peptide-1 Receptor Agonist Suppresses Muscle Fiber Necroptosis and Muscle Inflammation and Ameliorates Muscle Weakness in Experimental Polymyositis

    Mari Kamiya1, Fumitaka Mizoguchi1, Hirokazu Sasaki2, Natsuka Umezawa1 and Shinsuke Yasuda3, 1Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, 2Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, 3Tokyo Medical and Dental University (TMDU), Tokyo, Japan

    Background/Purpose: While glucocorticoids (GC) are the cornerstone of the treatment for polymyositis (PM), GC-induced myopathy is inevitable, which deteriorates muscle weakness. Therefore, novel therapeutic strategy…
  • Abstract Number: 1110 • ACR Convergence 2021

    Cryopyrin-associated Periodic Syndromes: GOSH and National Amyloidosis Centre Experience

    Ovgu Kul Cinar1, Charalampia Papadopoulou2, Amber Putland1, Karen Wynne1, Helen J Lachmann3, Despina Eleftheriou4 and Paul A. Brogan4, 1Great Ormond Street Hospital NHS Trust, London, United Kingdom, 2UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Infection, Immunology, and Rheumatology, London, United Kingdom, 3National Amyloidosis Centre, Royal Free Campus, UCL Medical School, London, United Kingdom, 4Great Ormond Street Hospital NHS Trust, UCL GOS Institute of Child Health, Department of Infection, Immunity & Inflammation, London, United Kingdom

    Background/Purpose: CAPS is a rare, heterogenous inflammasomopathy associated with gain-of-function mutations in NLRP3 that encodes cryopyrin. Mutations in NLRP3 result in excessive IL-1ß production that…
  • Abstract Number: 1564 • ACR Convergence 2021

    Nailfold Capillaroscopy Characterization in COVID-19: A Case Control Study

    Paola Estefania Bermudez Bermejo1, RODOLFO JIMENEZ-SOTO1, Alain Sanchez-Rodríguez1, Alonso Turrent1, Daniela Mercado- Velasco1, Ian Bravo-Lee1, Mariana Berenice Colli-Cortés2, Everardo Alvarez Hernandez3 and MaryCarmen Amigo1, 1CENTRO MEDICO ABC, Mexico City, Mexico, 2Hospital Regional "General Ignacio Zaragoza" ISSSTE, Mexico City, Mexico, 3HOSPITAL GENERAL DE MEXICO, Mexico City, Mexico

    Background/Purpose: Nailfold capillaroscopy is a relatively easy-to-access, low-cost clinical tool that could help identify early coagulopathy in subjects with SARS-CoV-2, but specific findings vs. controls…
  • Abstract Number: 0189 • ACR Convergence 2021

    Tapering and Discontinuation of Background Therapies During the Transition to Rilonacept Monotherapy in RHAPSODY, a Phase 3 Clinical Trial of Rilonacept in Patients with Recurrent Pericarditis

    Antonio Brucato1, Alistair Wheeler2, Sushil A. Luis3, Antonio Abbate4, Paul Cremer5, Fang Fang6, Antonella Insalaco7, Martin LeWinter8, Basil S. Lewis9, David Lin10, Stephen J. Nicholls11, Allan Klein5, Massimo Imazio12 and John F Paolini6, 1Department of Biomedical and Clinical Science, University of Milano, Fatebenefratelli Hospital, Milan, Italy, 2Kiniksa Pharmaceuticals, Ltd., Hamilton, Bermuda, 3Division of Cardiovascular Ultrasound, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, NY, 4VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, 5Department of Cardiovascular Imaging, Center for the Diagnosis and Treatment of Pericardial Diseases, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, 6Kiniksa Pharmaceuticals Corp., Lexington, MA, 7Department of Pediatric Medicine, Division of Rheumatology, Bambino Gesù Children's Hospital, Rome, Italy, 8Cardiology Unit, The University of Vermont Medical Center, The University of Vermont, Burlington, VT, 9Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center, Haifa, Israel, 10Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, 11MonashHeart, Department of Cardiology, Monash University, Clayton, Australia, 12University Cardiology, Cardiovascular and Thoracic Department, AOU Città della Salute e della Scienza di Torino, Torino, Italy

    Background/Purpose: Post-episode tapering of Standard of Care (SoC) medication in patients with recurrent pericarditis (RP) varies considerably. Gradual tapering of corticosteroids (CS) is recommended in…
  • Abstract Number: L03 • ACR Convergence 2020

    Efficacy and Safety of Deucravacitinib (BMS-986165), an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Active Psoriatic Arthritis: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial

    Philip Mease1, Atul Deodhar2, Désirée van der Heijde3, Frank Behrens4, Alan Kivitz5, Jonghyeon Kim6, Shalabh Singhal6, Miroslawa Nowak6 and Subhashis Banerjee6, 1Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 2Oregon Health & Science University, Portland, OR, 3Leiden University Medical Center, Leiden, Netherlands, 4CIRI/Rheumatology and Fraunhofer Institute IME, Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, 5Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, 6Bristol Myers Squibb, Princeton, NJ

    Background/Purpose: Tyrosine kinase 2 (TYK2) is an intracellular kinase that mediates signaling by key cytokines involved in psoriatic arthritis (PsA) pathophysiology. Deucravacitinib (BMS-986165) is a…
  • Abstract Number: L06 • ACR Convergence 2020

    Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis

    Maria C. Cid1, Sebastian Unizony2, Lara Pupim3, Fang Fang4, Joseph Pirrello3, Ai Ren4, Manoj Samant4, Teresa Zhou4 and John F Paolini4, 1Hospital Clinic Barcelona, Barcelona, Spain, 2Massachusetts General Hospital, Boston, MA, 3Kiniksa Pharmaceuticals, Lexington, MA, 4Kiniksa Pharmaceuticals, Lexington

    Background/Purpose: T helper (Th)1 and Th17 lymphocytes play a role in the pathogenesis of giant cell arteritis (GCA). Current treatments (e.g., corticosteroids and tocilizumab) target…
  • Abstract Number: 0015 • ACR Convergence 2020

    COVID -19 Lung Inflammation – What Have We Learnt so Far ?

    Sriya Gokaraju1, Maria Darda2, Vinod Vijayaraghavan Nalini Warrier3, Irina Duta3, Fiona Hayes3, Yasser Ahmed4 and Gouri Koduri3, 1Southend University Hospital NHS Trust, Essex, United Kingdom, 2Southend University Hospital NHS Trust, Essex, United Kingdom, 3Southend University Hospital NHS Trust, Essex, United Kingdom, 4Southend University Hospital, Essex, United Kingdom

    Background/Purpose: The SARS CoV-2 pandemic has inspired new interest in understanding the fundamental pathology of pneumonia and Acute Respiratory Distress Syndrome (ARDS). SARS CoV-2 in…
  • Abstract Number: 0410 • ACR Convergence 2020

    Exploring Gene Expression Profile of Primary Central Nervous System Vasculitis

    Carlo Salvarani1, Robert Brown2, Jonas Paludo2, Stefania Croci3, Stephen Ansell4, Caterina Giannini2, Joseph Parisi2, Kenneth Warrington2 and Gene Hunder2, 1Azienda USL-IRCCS di Reggio Emilia e Università di Modena e Reggio Emilia, Reggio Emilia, Italy, 2Mayo Clinic, Rochester, MN, 3Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy, 4Mayo Clinic, Rochester

    Background/Purpose: Primary CNS vasculitis (PCNSV) is an uncommon and poorly understood disease that affects the brain and spinal cord. It includes heterogeneous  histopathological patterns,  clinical…
  • Abstract Number: 0706 • ACR Convergence 2020

    Adenosine A2A Receptor Activation Reduces Markers of Chondrocyte Senescence and Cartilage Inflammation Associated with Osteoarthritis

    Benjamin Friedman1 and Bruce Cronstein2, 1NYU Rheumatology, New York, NY, 2NYU Grossman School of Medicine, New York, NY

    Background/Purpose: Osteoarthritis is an aging-associated disorder linked to dysfunctional metabolism, chronic inflammation, oxidative stress, and cellular senescence. Cellular senescence is associated with stable cell cycle…
  • Abstract Number: 0953 • ACR Convergence 2020

    Long-term Xanthine Oxidase Inhibitor Treat to Target Urate Lowering Therapy Coordinately Re-wires the Mononuclear Leukocyte Mitochondrial and Inflammatory Proteome in Gout

    Jacob Wozniak1, Ru Bryan2, David Gonzalez3 and Robert Terkeltaub4, 1UC San Diego, San Diego, CA, 2UCSD, San Diego, CA, 3UC San Diego, San Diego, CO, 4VA Medical Center/UC San Diego, San Diego, CA

    Background/Purpose: In gout, long-term xanthine oxidase inhibitor treat to target urate lowering therapy (XOIT2T) markedly reduces flares and synovitis, despite delayed resolution of tissue crystal…
  • Abstract Number: 1309 • ACR Convergence 2020

    Prevalence of Undiagnosed Axial Spondyloarthritis Among Patients with Inflammatory Bowel Disease: A Secondary Care Cross-Sectional Study

    Chong Seng Edwin Lim1, Mark Tremelling1, Louise Hamilton1, Alexander MacGregor1, Tom Turmezei1, Matthew Kim1 and Karl Gaffney2, 1Norfolk and Norwich University Hospital, Norwich, United Kingdom, 2Norfolk and Norwich University Hospital NHS Foundation Trust, Norfolk, United Kingdom

    Background/Purpose: Axial spondyloarthritis (axSpA) is closely related to inflammatory bowel disease (IBD), however contemporary data on the burden of hidden disease in the IBD population…
  • Abstract Number: 1648 • ACR Convergence 2020

    Comparison of Methotrexate and Glucosamine in Primary Knee Osteoarthritis with Inflammation

    Biswadip Ghosh1, Subhankar Haldar2 and Meghna Saha2, 1IPGME&R, Kolkata, Kolkata, West Bengal, India, 2IPGME&R, Kolkata, KOLKATA, India

    Background/Purpose: Many patients suffering from knee OA show swelling, warmth along with pain which are features of inflammation. There are no accepted pharmacological therapy for osteoarthritis…
  • « Previous Page
  • 1
  • …
  • 38
  • 39
  • 40
  • 41
  • 42
  • …
  • 67
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology